Zevra Therapeutics(ZVRA)
搜索文档
Zevra Therapeutics (ZVRA) Investor Presentation - Slideshow
2023-05-19 01:57
Corporate Presentation 1 May 2023 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "ant ...
Zevra Therapeutics(ZVRA) - 2023 Q1 - Quarterly Report
2023-05-16 05:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdict ...
Zevra Therapeutics(ZVRA) - 2022 Q4 - Earnings Call Transcript
2023-03-11 04:24
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Richard Pascoe - CEO LaDuane Clifton - Chief Financial Officer Travis Mickle - President and Co-Founder Christal Mickle - Chief Product Development Officer and Co-Founder Joshua Schafer - Chief Commercial Officer and Executive Vice President, Business Development Conference Call Participants Jonathan Aschoff - ROTH MKM Partners Louise Che ...
Zevra Therapeutics(ZVRA) - 2022 Q4 - Annual Report
2023-03-08 06:26
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File No. 001-36913 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of I ...
KemPharm (KMPH) Investor Presentation - Slideshow
2022-06-25 02:25
Management Presentation May 2022 11 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "an ...
KemPharm (KMPH) Investor Presentation - Slideshow
2022-05-17 00:40
Management Presentation March 2022 11 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," ...
KemPharm (KMPH) Investor Presentation - Slideshow
2021-10-02 03:39
ro INC KemPharm Management Presentation September 2021 Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of w ...